DONATE
GET INVOLVED
Drug Development Pipeline
Liprotamase
Status
DiscontinuedTherapeutic Approach
Nutritional-GI-Other
Liprotamase (Sollpura) is a pancreatic enzyme replacement that is not prepared from animal sources.
Status
Multiple phase 3 studies to look at the safety and effectiveness of liprotamase in people with CF ages 7 years and older have been completed.
A phase 3 study to look at the safety and effectiveness of a water-soluble formulation of liprotamase did not meet its primary endpoint. No further development is planned at this time.
Sponsor
This program is sponsored by Anthera Pharmaceuticals and partially funded by the Cystic Fibrosis Foundation. It is being conducted within the Therapeutics Development Network.
Latest News on Liprotamase
-
Cystic Fibrosis Foundation Therapeutics Announces $3 Million Award to Support Development of Pancreatic Enzyme Therapy
March 19, 2015
Learn moreCystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation, announced today a $3 million agreement with Anthera Pharmaceuticals Inc. to develop a porcine-free pancreatic enzyme therapy for people with CF who have pancreatic insufficiency.
-
-
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More